KAKEN PHARMACEUTICAL CO.,LTD. FY2027 Q1 Earnings Report

Quick View

Executive Summary

The key point this quarter was the significant acceleration in revenue and earnings growth driven by a sharp increase in licensing revenue. Revenue was ¥301.5B (+59.8% YoY), Operating Income was ¥109.0B (a substantial increase from ¥0.1B in the previous year), Ordinary Income was ¥112.6B (¥4.2B in the previous year), and Net Income was ¥84.4B (¥2.7B in the previous year). The primary factor was the recognition of ¥119.6B in licensing contract revenue in the Medicine Business, which substantially lifted the gross margin and profit margins.

Factors Affecting Performance

【Revenue】Revenue of ¥301.5B increased +59.8% YoY. The core Medicine segment accounted for ¥294.9B (97.8% of the total, +61.8% YoY), with ¥119.6B in licensing contract revenue driving the growth. Sales of proprietary products (sales of goods and products) were ¥175.3B, largely flat compared with ¥176.0B in the previous year. The Real Estate Business remained small but stable at ¥6.6B (+3.0% YoY).

【Profit and Loss】Operating Income of ¥109.0B increased substantially from ¥0.1B in the previous year, and the Operating Margin surged to 36.2% (less than 0.1% in the previous year). The gross margin improved to 69.5% (52.3% in the previous year), while the SG&A ratio declined to 33.4% (52.3% in the previous year), reflecting progress in fixed-cost dilution. Ordinary Income was ¥112.6B, with non-operating income primarily consisting of ¥3.1B in dividend income and therefore being recurring in nature. Extraordinary losses were minor at ¥0.1B, and Net Income of ¥84.4B consisted largely of profit generated by the core business. In conclusion, the Company achieved higher revenue and earnings, primarily due to licensing revenue, which has a strong one-off component and therefore warrants attention.

Segment Analysis

By segment, Medicine generated Revenue of ¥294.9B (97.8% of the total, +61.8% YoY), Operating Income of ¥105.3B (96.6% of the total, a substantial increase YoY), and a profit margin of 35.7%, driving nearly all of the current-period performance. Real Estate generated Revenue of ¥6.6B (+3.0% YoY) and Operating Income of ¥3.8B (+11.2% YoY), contributing steadily on a small but high-margin base with a profit margin of 57.2%. The business portfolio is highly dependent on Medicine, and fluctuations in licensing revenue have a significant impact on company-wide performance.

Key Financial Indicators

【Profitability】The Operating Margin of 36.2% and Net Profit Margin of 28.0% both improved substantially from the previous year, supported simultaneously by the increase in gross margin to 69.5% (52.3% in the previous year) and the decline in the SG&A ratio to 33.4% (52.3% in the previous year). 【Cash Flow Quality】R&D expenses were ¥46.0B, or 15.3% of Revenue, maintaining a standard level of investment for a pharmaceutical company, while non-operating income remained at 1.35% of Revenue, indicating that the vast majority of profit originated from the core business. 【Investment Efficiency】ROE was 5.5%, primarily due to the sharp increase in Net Profit Margin; however, the total asset turnover ratio remained low, leaving room for improvement in asset efficiency. 【Financial Soundness】With an Equity Ratio of 81.6% and cash and deposits of ¥521.5B, the financial foundation is extremely robust, and short-term liquidity risk is limited.

Cash Flow Analysis

As cash flow statement data is not included in the disclosed information, cash flow trends are analyzed based on changes in the balance sheet. Cash and deposits increased by ¥74.4B (+16.6%) YoY to ¥521.5B, further strengthening liquidity in line with the high profitability during the period. Meanwhile, accounts receivable and notes receivable were ¥203.6B, and inventories were ¥69.1B; working capital also expanded alongside Revenue growth, potentially resulting in a certain time lag before profits are converted into cash. Total assets increased to ¥1874.1B (¥1782.2B in the previous year), with much of the increase consisting of accumulated working capital and cash. Interest-bearing debt consisted solely of ¥38.5B in short-term borrowings, and cash substantially exceeded this amount, indicating limited concerns regarding liquidity.

Quality of Earnings

The vast majority of current-period profit was based on recurring business activities. Non-operating income of ¥4.1B (1.35% of Revenue) primarily consisted of ¥3.1B in dividend income and ¥0.9B in interest income, indicating limited dependence on unusual one-off income. Extraordinary losses were minor at ¥0.1B (including losses on disposal of fixed assets and other items), and the divergence between Ordinary Income and Net Income was also limited. However, the high profitability during the period was primarily attributable to the recognition of ¥119.6B in licensing contract revenue in the Medicine segment. As this revenue depends on the timing of contracts, uncertainty remains regarding its reproducibility from the next fiscal year onward. In addition, although the increase in accounts receivable and inventories is a natural result of Revenue growth, there may be a timing gap between profit recognition and cash collection. Monitoring working capital trends is therefore useful in evaluating earnings quality.

Earnings Forecast and Guidance

The Full-Year forecast is Revenue of ¥899.0B (+17.0% YoY), Operating Income of ¥79.0B, Ordinary Income of ¥86.0B, EPS of ¥171.65, and DPS of ¥190. As of Q1, progress rates were 33.5% for Revenue, 138.0% for Operating Income, and 130.0% for Net Income, representing a pace substantially ahead of the Full-Year forecast. This significant front-loaded progress appears to have been primarily caused by the concentration of licensing contract revenue recognition in Q1, suggesting that the Full-Year forecast may have been conservatively set based on an expected reversal of this temporary revenue and increased R&D expenses. As of the current quarter, no revisions have been made to the earnings or dividend forecasts.

Shareholder Returns

Under the Company’s plan, annual dividends are expected to be ¥190 (¥95 in the previous year). Based on approximately 37.868M average shares outstanding during the period, the annual dividend payout is estimated at approximately ¥7.19B, resulting in a Payout Ratio of approximately 111% against the Full-Year Net Income plan of ¥65.0B, a level exceeding 100%. With cash and deposits of ¥521.5B and an Equity Ratio of 81.6%, the financial foundation is robust and there are limited concerns regarding short-term dividend payment capacity. However, the planned Payout Ratio exceeds the earnings level, and its consistency with sustainable earnings growth will be a medium-term issue. This section addresses the Payout Ratio based solely on dividends and distinguishes it from the Total Return Ratio, which includes share repurchases.

Risk Factors

1. Dependence on licensing revenue: Licensing contract revenue accounted for approximately 40% (¥119.6B) of current-period Revenue, creating a structure in which performance is significantly affected by the timing of contracts. A decline in subsequent quarters could substantially reduce the earnings growth rate.

2. Concentration of the business portfolio: The Medicine segment accounts for 97.8% of Revenue and 96.6% of Operating Income, leaving limited support from business diversification. Sensitivity to the segment’s pipeline progress and drug price trends is high.

3. Expansion of working capital: Accounts receivable and notes receivable of ¥203.6B and inventories of ¥69.1B have increased alongside Revenue growth, potentially creating a time lag between profit recognition and cash collection. Progress in future collections and inventory reduction will warrant attention.

Industry Benchmark (For Reference; Compiled by the Company)

Industry Benchmark (pharma)

Profitability and Returns

Profitability substantially exceeded the industry median, with licensing revenue during the quarter establishing an exceptionally high level even within the industry.

Growth and Capital Efficiency

The Revenue growth rate also substantially exceeded the industry median, although it should be interpreted in light of the significant impact of one-off licensing revenue.

※Source: Compiled by the Company

Key Points in the Earnings Results

1. The high profitability during the quarter was primarily attributable to the recognition of ¥119.6B in licensing contract revenue in the Medicine segment (approximately 40% of Revenue). The data confirms that the sharp increases in Operating Margin to 36.2% and Net Profit Margin to 28.0% include one-off factors.

2. Progress against the Full-Year forecast was substantially ahead at 138.0% for Operating Income and 130.0% for Net Income. Given that no revisions have been made to the earnings or dividend forecasts, the presence or absence of a revenue reversal in subsequent quarters will be a key point of focus in the earnings data.

3. The planned Payout Ratio is approximately 111%. The contrast with the robust financial foundation, represented by cash and deposits of ¥521.5B and an Equity Ratio of 81.6%, is a distinctive structure evident from the earnings data.

Theoretical Share Price (Reference Value)

This is a mechanically calculated reference range based solely on publicly disclosed data using a residual income model (Ohlson type with an explicit 5-year fade). It is not a forecast of the market share price or a recommendation of any specific investment action.

Sensitivity: ¥3,414–¥3,598 at ±1% for the Cost of Equity, and ¥3,488–¥3,514 at ±0.1 for ω.

Notes:

• Because Net Income progress against the Full-Year forecast (130%) exceeds the standard level (25%), Forecast EPS has been adjusted upward within a maximum range of +10% (because companies with front-loaded progress tend to outperform their forecasts; adjustments may be excessive for highly seasonal businesses).
• Because forecast ROE is below the Cost of Equity, the theoretical value is below Book Value per Share.
• Net assets as of the quarter-end are used (there is a timing difference from the Full-Year forecast).
• Because net assets include non-controlling interests, the theoretical value may be calculated somewhat higher.

(Calculation model: Residual income model / Interest rate reference month: 2026-07 / This value does not forecast or guarantee the future share price)

---

This report is an earnings analysis document automatically generated by AI based on XBRL earnings release data. It is not a recommendation to invest in any specific security. The industry benchmarks are reference information compiled by the Company based on publicly disclosed earnings data. Investment decisions should be made at your own responsibility, after consulting professionals as necessary.

---End of Report---